Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Enliven Therapeutics, Inc. (ELVN)

Enliven Therapeutics Q3 net loss widens to $27.7 million; FDA aligned on ENABLE-2

Negative Impact 3 of 5 earnings Written later

Enliven Therapeutics reported a third-quarter 2026 net loss of $27.7 million, up from $20.1 million a year earlier, as research and development and general and administrative expenses rose. The company said it reached alignment with the FDA on the final design of its ENABLE-2 pivotal Phase 3 trial and remains on track to start the trial before year-end 2026, with $884.4 million in cash, cash equivalents and marketable securities expected to fund operations into 2030.

Key points

  • Q3 2026 net loss was $27.7 million, or $0.36 per share, versus $20.1 million, or $0.32 per share, in Q3 2025
  • R&D expenses were $28.0 million in Q3 2026, compared with $18.2 million in Q3 2025
  • Cash, cash equivalents and marketable securities totaled $884.4 million as of September 30, 2026, with runway expected into 2030
  • ENABLE-2 start is targeted before year-end 2026 following FDA alignment on trial design

The filing

CompanyEnliven Therapeutics, Inc. (ELVN)
Form8-K, current report
Filed with the SECNov 5, 2026, 4:10 PM ET
Accession number0001193125-26-449819

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 05, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.